Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) have received a consensus rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $311.67.
Several equities analysts recently commented on CRL shares. Argus set a $330.00 target price on shares of Charles River Laboratories International in a research note on Thursday, September 17th. Wall Street Zen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Mizuho increased their price objective on Charles River Laboratories International from $264.00 to $295.00 and gave the company a “neutral” rating in a report on Friday, September 25th. Royal Bank Of Canada raised their target price on shares of Charles River Laboratories International from $322.00 to $352.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Finally, UBS Group lifted their target price on shares of Charles River Laboratories International from $357.00 to $387.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th.
View Our Latest Research Report on Charles River Laboratories International
Charles River Laboratories International Price Performance
Shares of CRL stock opened at $314.29 on Thursday. Charles River Laboratories International has a twelve month low of $146.20 and a twelve month high of $379.63. The firm has a fifty day simple moving average of $316.09 and a 200-day simple moving average of $231.19. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $15.06 billion, a PE ratio of 345.37, a price-to-earnings-growth ratio of 2.84 and a beta of 1.36.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The business had revenue of $982.73 million for the quarter, compared to analysts’ expectations of $960.36 million. During the same period in the prior year, the firm earned $2.43 EPS. The business’s quarterly revenue was down 2.2% on a year-over-year basis. Equities research analysts anticipate that Charles River Laboratories International will post 11.45 earnings per share for the current fiscal year.
Insider Activity
In related news, EVP Shannon M. Parisotto sold 2,156 shares of the company’s stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 24,042 shares of the business’s stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total value of $8,414,700.00. Following the completion of the transaction, the director directly owned 31,596 shares in the company, valued at approximately $11,058,600. This represents a 43.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 60,740 shares of company stock valued at $19,528,128 in the last ninety days. Insiders own 1.30% of the company’s stock.
Institutional Investors Weigh In On Charles River Laboratories International
Several large investors have recently made changes to their positions in CRL. Physician Wealth Advisors Inc. raised its stake in Charles River Laboratories International by 127.9% during the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 55 shares in the last quarter. Continuum Advisory LLC bought a new stake in Charles River Laboratories International during the 2nd quarter valued at about $30,000. IFP Advisors Inc increased its holdings in Charles River Laboratories International by 182.8% during the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after purchasing an additional 106 shares during the period. Dogwood Wealth Management LLC bought a new stake in shares of Charles River Laboratories International in the third quarter valued at about $56,000. Finally, Cavanaugh Group Inc. purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $65,000. 98.91% of the stock is owned by institutional investors.
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
